In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
Tuberculosis is a contagious bacterial infection primarily caused by Mycobacterium tuberculosis. It affects the lungs but can also affect other parts of the body. Tuberculosis remains a significant global health concern, necessitating ongoing research and clinical trials to develop effective treatments and vaccines, such as the polyantigenic, liposomized vaccine RUTI®
How does the design of the RUTI® vaccine, characterized by its polyantigenic and liposomized features, impact its effectiveness in combating tuberculosis?
AGENT-BASED MODEL: Dynamic simulations
Virtual patient population Immune System and Tuberculosis disease trajectory – Virtual tuberculosis patient population simulation of tuberculosis disease progression, mono- and combination therapy.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved